A phase II open-label multicentre study of the efficacy of ZD1839 (Iressa (TM)) in combination with irradiation followed by chemotherapy in patients with inoperable stage III non small cell lung cancer

Trial Profile

A phase II open-label multicentre study of the efficacy of ZD1839 (Iressa (TM)) in combination with irradiation followed by chemotherapy in patients with inoperable stage III non small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
    • 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top